FAST NEWS: Zai Lab Acquires Exclusive Greater China License for Cervical Cancer Drug
The latest: Biotech drug maker Zai Lab Ltd. (9688.HK; ZLAB.US) announced on Tuesday that one of its subsidiaries has obtained an exclusive license to develop and commercialize Seagen Inc.’s (SGEN.US) cervical cancer…
RELATED ARTICLES
-
Joinn profits slide as lab monkey build-up backfires
6127.HK 603127.SHG
-
HBM gets health boost from drug licensing deals
2142.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
-
New Horizon Health finds formula for profits ahead of schedule
6606.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
FAST NEWS: Zai Lab’s loss narrows on strengthening sales
9688.HK ZLAB.US
Discover hidden China stock gems in our weekly newsletter